# LiberoThera Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/liberothera-co

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Website: www.liberothera.com/
- Total disclosed funding: $7.6M
- Latest round: Series C (Aug 6, 2021)
- Investors on record: 5

## About

Based in Tokyo, Japan, LiberoThera Co., Ltd. focuses on innovative drug development utilizing proprietary technologies for membrane protein production, targeting critical areas such as cancer treatment and therapeutic applications.LiberoThera Co., Ltd. was founded in 2018 in Tokyo, Japan. The company specializes in drug development and has completed a total of 3 deals since its inception. On August 1, 2024, it raised JPY 720 million in funding from investors including Taiho Ventures, MP Healthcare Venture Management, and UTokyo Innovation Platform, totaling JPY 720 million raised to date.LiberoThera Co., Ltd. specializes in innovative drug development through its proprietary cell-free membrane protein preparation technology and non-natural amino acid incorporation technology. These advanced methodologies facilitate the production of complex membrane proteins that are critical for drug discovery and development, particularly in areas such as cancer treatment and other therapeutic applications. The company's core offerings aim to improve the efficiency and effectiveness of drug candidates, thereby addressing significant medical needs in oncology and potentially other therapeutic areas. LiberoThera's products serve a diverse clientele, including pharmaceutical companies and research institutions, primarily in North America and Asia, focusing on markets where there is a high demand for biopharmaceutical solutions.LiberoThera operates within a revenue framework that emphasizes partnerships and collaborative research agreements with its clients, predominantly in the biopharmaceutical sector. These transactions often involve B2B arrangements where LiberoThera provides its specialized technologies and expertise in exchange for funding or equity stakes in jointly developed products. The firm engages in strategic collaborations that can result in milestone payments and royalties based on the commercial success of developed therapies. While specific pricing plans and revenue figures for individual products and services are not disclosed, the company's revenue is expected to be driven by these collaborative efforts, underscoring its commitment to fostering innovation in drug development through strategic alliances.In August 2024, LiberoThera Co., Ltd. raised JPY 720 million in venture funding to accelerate drug discovery research and development. The funding will support the design and launch of upcoming products and expand the company’s reach into new markets, particularly in North America and Asia, by leveraging their proprietary technologies to meet emerging medical needs. Specific release dates for new products are yet to be announced.

## Funding rounds

- Series C, Aug 6, 2021, $2.7M — Taiho Ventures
- Series C, May 17, 2021, $4.9M — MP Healthcare Venture Management, Beyond Next Ventures, Miyagin Venture Capital, UTokyo Innovation Platform

## Investors

- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Series C
- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Series C
- Miyagin Venture Capital (https://capitalatlas.ai/funds/miyagin-venture-capital) — Series C
- UTokyo Innovation Platform (https://capitalatlas.ai/funds/utokyo-innovation-platform) — Series C
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series C